Literature DB >> 16930665

Determinants of activity of the HIV-1 maturation inhibitor PA-457.

Feng Li1, Dorian Zoumplis, Claudia Matallana, Nicole R Kilgore, Mary Reddick, Abdul S Yunus, Catherine S Adamson, Karl Salzwedel, David E Martin, Graham P Allaway, Eric O Freed, Carl T Wild.   

Abstract

3-O-(3',3'-dimethylsuccinyl) betulinic acid, also termed PA-457 or DSB, is a novel HIV-1 inhibitor that blocks virus maturation by disrupting cleavage of the capsid precursor, CA-SP1. To better define the molecular target for PA-457, we prepared a panel of mutant viruses with point deletions spanning the CA-SP1 cleavage domain and characterized each of these viruses for PA-457 sensitivity. Our results indicate that amino acid residues in the N-terminal half of SP1 serve as determinants of PA-457 activity, while residues in the C-terminal half of SP1 were not involved in compound activity. These findings support and extend previous observations that PA-457 is a specific inhibitor of CA-SP1 cleavage and identify the CA-SP1 domain as the primary viral determinant for this novel inhibitor of HIV-1 replication.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16930665     DOI: 10.1016/j.virol.2006.07.023

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  35 in total

1.  Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1.

Authors:  Kurt Van Baelen; Karl Salzwedel; Evelien Rondelez; Veerle Van Eygen; Stephanie De Vos; Ann Verheyen; Kim Steegen; Yvan Verlinden; Graham P Allaway; Lieven J Stuyver
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

Review 2.  The structural biology of HIV assembly.

Authors:  Barbie K Ganser-Pornillos; Mark Yeager; Wesley I Sundquist
Journal:  Curr Opin Struct Biol       Date:  2008-04-09       Impact factor: 6.809

3.  Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly.

Authors:  Katrina J Heyrana; Boon Chong Goh; Juan R Perilla; Tam-Linh N Nguyen; Matthew R England; Maria C Bewley; Klaus Schulten; Rebecca C Craven
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

Review 4.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

5.  Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease.

Authors:  Zhigang Liu; Yong Wang; Joseph Brunzelle; Iulia A Kovari; Ladislau C Kovari
Journal:  Protein J       Date:  2011-03       Impact factor: 2.371

Review 6.  Maturation of retroviruses.

Authors:  Owen Pornillos; Barbie K Ganser-Pornillos
Journal:  Curr Opin Virol       Date:  2019-06-08       Impact factor: 7.090

Review 7.  HIV-1 Capsid Inhibitors as Antiretroviral Agents.

Authors:  Suzie Thenin-Houssier; Susana T Valente
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

8.  Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.

Authors:  Catherine S Adamson; Michael Sakalian; Karl Salzwedel; Eric O Freed
Journal:  Retrovirology       Date:  2010-04-20       Impact factor: 4.602

9.  Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).

Authors:  Catherine S Adamson; Kayoko Waki; Sherimay D Ablan; Karl Salzwedel; Eric O Freed
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

10.  The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain.

Authors:  Sandrina Dafonseca; Pascale Coric; Bernard Gay; Saw See Hong; Serge Bouaziz; Pierre Boulanger
Journal:  Virol J       Date:  2008-12-23       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.